Skip to main content

Institutional intelligence for IPCA Laboratories Ltd.

Cross-view mutual fund activity and super-investor shareholding · Jun 2026 SHP.

Ownership breakdown

Category totals from the official quarterly Shareholding Pattern filing (Jun 2026). Sums to 100.00%.

  • Promoters44.72%
  • FII10.73%
  • Mutual Funds31.15%
  • DII (ex-MF)6.22%
  • Retail & others7.18%
  • 1% Club 6.27%(subset)

Super Investors and 1% Club names below are disclosed holders at or above 1%. They are subsets of the categories above, not additive. View filing

Holder details (≥1% disclosed names)

Promoters

Promoter & promoter group

44.72%5 named
HolderStakeSharesValue (₹ Cr)
25.49%6,46,65,448
6.61%1,67,70,000
5.50%1,39,56,010
2.29%58,14,680
1.70%43,02,000

Mutual Funds

Domestic mutual funds & UTI

31.15%6 named
HolderStakeSharesValue (₹ Cr)
9.54%2,42,02,611
6.36%1,61,41,739
4.64%1,17,77,408
2.79%70,83,656
1.94%49,11,931
1.05%26,76,396

FII / FPI

Foreign portfolio investors

10.73%2 named
HolderStakeSharesValue (₹ Cr)
1.14%28,95,885
1.03%26,22,997

1% Club — Individuals & others

Non-promoter ≥1% holders not matched to a curated profile

6.27%3 named
HolderStakeSharesValue (₹ Cr)
3.69%93,72,522
1.39%35,17,311
1.19%30,19,905

Retail & others

Holders below 1% disclosure threshold and public non-institutions

7.18%

SEBI requires naming only shareholders with ≥1% stake. The remaining 7.18% includes retail investors, small HNIs, employee trusts, and other holders below the disclosure threshold — aggregated in the official filing.

DII (other)

Insurance, banks, AIF, other domestic institutions

6.22%No names

No named holders ≥1% in this bucket.

Super Investors

Curated tracked investor profiles

No names

No curated super investor holds ≥1% in the latest filing. See FII, DII, and mutual fund holders in the sections above.

Shareholding data sourced from NSE/BSE regulatory filings. Category chart uses official filing totals; named holder lists include every disclosed ≥1% position. Not investment advice. See our disclaimer and methodology.